Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07824167 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation

Name: The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation — clinical trial record (NCT07824167)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorEmory University

Started2026-09

View on ClinicalTrials.gov ↗

Emory University

371 trials monitored

See 23 trials at risk

Clesrovimab is an FDA-approved antibody drug recommended for infants younger than 8 months who are entering their first respiratory syncytial virus (RSV) season and whose mothers did not receive an RSV vaccine during pregnancy. It is given to help prevent severe RSV illness. This study will measure clesrovimab and other RSV antibodies in infants' blood and noses to learn how much of the drug reaches the nose, how long the antibodies remain, and how antibody levels change if an infant becomes infected with RSV.

Trial Details

NCT Number	NCT07824167
Lead Sponsor	Emory University Collaborators: Merck Sharp & Dohme LLC
Conditions	RSV Infection
Enrollment	24 participants
Start Date	2026-09
Primary Completion	2028-03 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-09-17